| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Vantictumab | OMP-18R5; anti-Fzd7 | Phase 1 Clinical | Bayer AG, Oncomed Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Osteopetrosis; Pancreatic Neoplasms; Solid tumours | Details |